Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Liang ^a   Zhang, Zhongwei ^a   Mason, Ralph P ^a   Sarkaria, Jann N ^b   Zhao, Dawen ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CONTRAST MEDIUM; MANGANESE; NANOPARTICLE; ORGANOARSENIC DERIVATIVE; OXIDE;

CHEMISTRY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; GLIOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; RADIOGRAPHY; TUMOR CELL LINE;

ARSENICALS; CELL LINE, TUMOR; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MANGANESE; NANOPARTICLES; OXIDES; RADIOGRAPHY;

EID: 84929192156     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09874     Document Type: Article

References (50)

1. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2011., (2013) (Date of access: 14/06/2013), http://seer.cancer.gov/ csr/1975-2011/.
2. Wen, P.Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492-507 (2008).
3. Park, S. et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res. 69, 2809-2816 (2009).
4. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
5. Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012).
6. Kim, J. et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 23, 23-34 (2013).
7. Zhen, Y., Zhao, S., Li, Q., Li, Y. & Kawamoto, K. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stemlike cell population in gliomas. Cancer Lett. 292, 64-72 (2010).
8. Wu, J. et al. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway. Toxicology letters 220, 61-69 (2013).
9. Miller, W. H., Jr., Schipper, H. M., Lee, J. S., Singer, J. & Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893-3903 (2002).
10. Grimm, S. A. et al. Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. J. Neurooncol. 110, 237-243 (2012).
11. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug. Discov. 4, 145-160 (2005).
12. Pastorino, F. et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 63, 86-92 (2003).
13. Gabizon, A. A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19, 424-436 (2001).
14. Zhang, L. & Zhao, D. Applications of nanoparticles for brain cancer imaging and therapy. J. Biomed. Nanotechnol. 10, 1713-1731 (2014).
15. Allen, T. M. & Cullis, P. R. Drug delivery systems: entering the mainstream. Science 303, 1818-1822 (2004).
16. Swindell, E. P., Hankins, P. L., Chen, H., Miodragovic, D. U. & O'Halloran, T. V. Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes. Inorganic chemistry 52, 12292-12304 (2013).
17. Chen, H. et al. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J. Am. Chem. Soc. 128, 13348-13349 (2006).
18. Shapiro, E. M. & Koretsky, A. P. Convertible manganese contrast for molecular and cellular MRI. Magn. Reson. Med. 60, 265-269 (2008).
19. Kim, T. et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J. Am. Chem. Soc. 133, 2955-2961 (2011).
20. Pan, D. et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J. Am. Chem. Soc. 130, 9186-9187 (2008).
21. Zhang, L., Zhou, H., Belzile, O., Thorpe, P. & Zhao, D. Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. J. Control Release 183C, 114-123 (2014).
22. Zhang, L. & Zhao, D. Liposomal encapsulation enhances in vivo near infrared imaging of exposed phosphatidylserine in a mouse glioma model. Molecules 18, 14613-14628 (2013).
23. Ran, S., Downes, A. & Thorpe, P. E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 62, 6132-6140 (2002).
24. Zhao, D., Stafford, J. H., Zhou, H. & Thorpe, P. E. Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model. Transl. Oncol. 4, 355-364 (2011).
25. Zhou, H. et al. Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging. J. Biomed. Nanotechnol. 10, 846-855 (2014).
26. Hammill, A. K., Uhr, J. W. & Scheuermann, R. H. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp. Cell. Res. 251, 16-21 (1999).
27. Mirnikjoo, B., Balasubramanian, K. & Schroit, A. J. Mobilization of lysosomal calcium regulates the externalization of phosphatidylserine during apoptosis. J. Biol. Chem. 284, 6918-6923 (2009).
28. Abbott, B. J. et al. Microbial transformation of A23187, a divalent cation ionophore antibiotic. Antimicrob Agents Chemother 16, 808-812 (1979).
29. Carlson, B. L. et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int. J. Radiat. Oncol. Biol. Phys. 75, 212-219 (2009).
30. Cheung, B. C., Sun, T. H., Leenhouts, J. M. & Cullis, P. R. Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim. Biophys. Acta. 1414, 205-216 (1998).
31. Abraham, S. A. et al. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim. Biophys. Acta. 1565, 41-54 (2002).
32. Viglianti, B. L. et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn. Reson. Med. 51, 1153-1162 (2004).
33. Kheirolomoom, A. et al. Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasoundmediated hyperthermia. J. Control Release 172, 266-273 (2013).
34. Bennewitz, M. F. et al. Biocompatible and pH-sensitive PLGA encapsulated MnO nanocrystals for molecular and cellular MRI. ACS Nano. 5, 3438-3446 (2011).
35. Tilcock, C., Unger, E., Cullis, P. & MacDougall, P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology 171, 77-80 (1989).
36. Hagberg, G. E. & Scheffler, K. Effect of r(1) and r(2) relaxivity of gadolinium-based contrast agents on the T(1)-weighted MR signal at increasing magnetic field strengths. Contrast Media Mol Imaging 8, 456-465 (2013).
37. Taggar, A. S. et al. Copper-topotecan complexation mediates drug accumulation into liposomes. J. Control Release 114, 78-88 (2006).
38. Langereis, S., Geelen, T., Grull, H., Strijkers, G. J. & Nicolay, K. Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. NMR Biomed. 26, 728-744 (2013).
39. Lee, S. M. et al. Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release. Angew. Chem. Int. Ed. Engl. 49, 9960-9964 (2010).
40. Ding, H. & Wu, F. Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics 2, 1040-1053 (2012).
41. Chakravarty, R., Hong, H. & Cai, W. Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives. Mol. Pharm. 11, 3777-3797 (2014).
42. Viglianti, B. L. et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn. Reson. Med. 56, 1011-1018 (2006).
43. Ponce, A. M. et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J. Natl. Cancer Inst. 99, 53-63 (2007).
44. Kroll, R. A. & Neuwelt, E. A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42, 1083-1099; discussion 1099-1100 (1998).
45. Jain, R. K. et al. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610-622 (2007).
46. Meyers, J. D., Doane, T., Burda, C. & Basilion, J. P. Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond) 8, 123-143 (2013).
47. He, J., Yin, Y., Luster, T. A., Watkins, L. & Thorpe, P. E. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin. Cancer Res. 15, 6871-6880 (2009).
48. Schwendener, R. A., Wuthrich, R., Duewell, S., Wehrli, E. & von Schulthess, G. K. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest. Radiol. 25, 922-932 (1990).
49. Griffin, R. J., Williams, B. W., Park, H. J. & Song, C. W. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 61, 1516-1522 (2005).
50. Alhasan, M. K., Liu, L., Lewis, M. A., Magnusson, J. & Mason, R. P. Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors. PLoS One 7, e46106 (2012).